Associations between elevated kidney and liver biomarker ratios, metabolic syndrome and all-cause and coronary heart disease (CHD) mortality: analysis of the U.S. National Health and Nutrition Examination Survey (NHANES)

BMC Cardiovascular Disorders

Akinkunle Oye-Somefun¹  Jennifer L. Kuk¹  Chris I. Ardern¹ 

[1] School of Kinesiology and Health Science, 222A Bethune College, York University, 4700 Keele Street, M3J1P3, Toronto, ON, Canada;

关键词: Biomarkers;    Kidney function;    Metabolic syndrome;    Mortality;    NHANES;    Obesity;   

DOI  :  10.1186/s12872-021-02160-w

来源: Springer

【 摘 要 】

BackgroundWe examined the relationship between ratios of select biomarkers of kidney and liver function on all-cause and coronary heart disease (CHD) mortality, both in isolation, and in combination with metabolic syndrome (MetS), among adults (20 + years, n = 10,604).MethodsData was derived from the U.S. National Health and Nutrition Examination Survey (1999–2016) including public-use linked mortality follow-up files through December 31, 2015.ResultsSelect biomarker ratios of kidney (UACR or albuminuria and BUN-CR) and liver (AST-ALT and GGT-ALP) function in isolation and in combination with MetS were associated with all-cause and CHD mortality. Compared to individuals with neither elevated biomarker ratios nor MetS (HR = 1.00, referent), increased risk of all-cause mortality was observed in the following groups: MetS with elevated UACR (HR, 95% CI = 2.57, 1.99–3.33), MetS with elevated AST-ALT (HR = 2.22, 1.61–3.07), elevated UACR without MetS (HR = 2.12, 1.65–2.72), and elevated AST-ALT without MetS (HR = 1.71, 1.35–2.18); no other biomarker ratios were associated with all-cause mortality. For cause-specific deaths, elevated risk of CHD mortality was associated with MetS with elevated UACR (HR = 1.67, 1.05–2.67), MetS with elevated AST-ALT (HR = 2.80, 1.62–4.86), and elevated BUN-CR without MetS (HR = 2.12, 1.12–4.04); no other biomarker ratios were associated with CHD mortality.ConclusionFuture longitudinal studies are necessary to examine the utility of these biomarker ratios in risk stratification for chronic disease management.

【 授权许可】

CC BY